NYXH
Nyxoah SA
$1.39
-6.71%
$60.7M
No data for this timeframe.
Vol
Market Cap$60.7M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (79%)
SEC Reports6
Press Releases3
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. C9·CIK 0001857190·Prev Close $1.49
Recent Activity
Jun 11, 2026
SEC
Nyxoah SA filed a 6-K on June 11, 2026, disclosing the issuance of 55,232,558 new shares in connection with its previous
6-K — Impact 7/10
Jun 10, 2026
other
Information on the total number of voting rights and shares
<p align="right"><b>REGULATED INFORMATION</b></p>
Jun 8, 2026
SEC
Nyxoah priced a $95M gross underwritten public offering of 55.2M ordinary shares at $1.72/share, representing ~126% dilu
6-K — Impact 7/10
Jun 8, 2026
SEC
Nyxoah is raising approximately $88.5 million net (€76.3 million) from a public offering of 55.2 million ordinary shares
424B5 — Impact 7/10
Jun 5, 2026
Press
Nyxoah priced a $95M underwritten public offering of ~55.2M shares at $1.72/share, a ~24% discount to the prior close im
Impact 7/10
Mar 19, 2026
Press
Nyxoah reported strong fourth-quarter and full-year 2025 financial results, driven by the first full quarter of U.S. com
Impact 8/10
Price Targets
$8.96
+544.5% upside
Strong Buy
Current $1.39
Low $4.95
Median $8.99
High $12.89
4 analysts
$4.95
$12.89
Analyst Ratings
4Strong Buy
7Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 13, 2026 | Piper Sandler | REITERATE | Overweight → Overweight |
| May 12, 2026 | Stifel | DOWNGRADE | Buy → Hold |
| Apr 10, 2026 | Stifel | MAINTAIN | Buy → Buy |
| Mar 23, 2026 | Cantor Fitzgerald | REITERATE | Overweight → Overweight |
| Mar 20, 2026 | Stifel | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.44 ▲ +11.0% | $-0.49 — $-0.34 | 21% YoY | 5 |
| Next Q | $-0.36 ▲ +19.0% | $-0.45 — $-0.31 | 42% YoY | 5 |
| Current FY | $-1.52 ▲ +10.8% | $-1.73 — $-1.41 | 36% YoY | 5 |
| Next FY | $-1.15 ▲ +11.1% | $-1.38 — $-0.96 | 25% YoY | 5 |
Latest Reports
BEARISH
6-K
7/10
Nyxoah SA filed a 6-K on June 11, 2026, disclosing the issuance of 55,232,558 new shares in connection with its previous
Jun 11, 2026
BEARISH
6-K
7/10
Nyxoah priced a $95M gross underwritten public offering of 55.2M ordinary shares at $1.72/share, representing ~126% dilu
Jun 8, 2026
BEARISH
Press
7/10
Nyxoah priced a $95M underwritten public offering of ~55.2M shares at $1.72/share, a ~24% discount to the prior close im
Jun 5, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
6 SEC filing reports analyzed. Sentiment: 1 bullish, 4 bearish, 1 mixed, 0 neutral. Avg impact: 6.5/10.
BEARISH
6-K
7/10
Nyxoah SA filed a 6-K on June 11, 2026, disclosing the issuance of 55,232,558 new shares in connecti
Jun 11, 2026
BEARISH
6-K
7/10
Nyxoah priced a $95M gross underwritten public offering of 55.2M ordinary shares at $1.72/share, rep
Jun 8, 2026
BEARISH
424B5
7/10
Nyxoah is raising approximately $88.5 million net (€76.3 million) from a public offering of 55.2 mil
Jun 8, 2026
BEARISH
424B5
7/10
Nyxoah filed a preliminary prospectus supplement (424B5) for an underwritten follow-on offering of o
Jun 4, 2026
BULLISH
PRESS-RELEASE
5/10
Nyxoah reported Q1 2026 EPS of $-0.37, beating consensus of $-0.44 (15.5% beat), while revenue of $7
May 20, 2026
MIXED
PRESS-RELEASE
6/10
Nyxoah reported Q1 2026 revenue of €6.4M, up from €1.1M YoY, driven by U.S. Genio launch, but EPS of
May 12, 2026
BEARISH
7/10
Nyxoah priced a $95M underwritten public offering of ~55.2M shares at $1.72/share, a ~24% discount t
Jun 5, 2026
BULLISH
8/10
Nyxoah reported strong fourth-quarter and full-year 2025 financial results, driven by the first full
Mar 19, 2026
NEUTRAL
3/10
Nyxoah announced it will release its fourth quarter and full year 2025 financial results on March 19
Mar 5, 2026
Current analyst consensus: Buy (79% buy). Based on 14 analysts: 4 strong buy, 7 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$8.96 mean target
+544.5% upside
Strong Buy (2.00)
$4.95 Low
$12.89 High
| Metric | Value |
|---|---|
| Current Price | $1.39 |
| Target Low | $4.95 |
| Target Mean | $8.96 |
| Target Median | $8.99 |
| Target High | $12.89 |
| # Analysts | 4 |
| Recommendation | Strong Buy (2.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.44 | $-0.49 | $-0.34 | 20.8% | +11.0% | 3↑ 0↓ | $0.0B | 464.8% | 5 |
| Next Q 2026-09-30 |
$-0.36 | $-0.45 | $-0.31 | 42.4% | +19.0% | 3↑ 0↓ | $0.0B | 398.6% | 5 |
| Current FY 2026-12-31 |
$-1.52 | $-1.73 | $-1.41 | 35.6% | +10.8% | 3↑ 0↓ | $0.0B | 273.2% | 5 |
| Next FY 2027-12-31 |
$-1.15 | $-1.38 | $-0.96 | 24.6% | +11.1% | 2↑ 2↓ | $0.1B | 96.1% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.437 | |
| 7d ago | $-0.507 | +0.070 |
| 30d ago | $-0.491 | +0.054 |
| 60d ago | $-0.569 | +0.132 |
| 90d ago | $-0.569 | +0.132 |
3 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 13, 2026 | Piper Sandler | REITERATE | Overweight | Overweight |
| May 12, 2026 | Stifel | DOWNGRADE | Buy | Hold |
| Apr 10, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Mar 23, 2026 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| Mar 20, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Jan 29, 2026 | Stifel | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 7 | 3 | 0 | 0 | 79% | |
| May 1, 2026 | 4 | 7 | 3 | 0 | 0 | 79% | |
| Apr 1, 2026 | 4 | 7 | 3 | 0 | 0 | 79% | |
| Mar 1, 2026 | 4 | 7 | 3 | 0 | 0 | 79% | |
| Feb 1, 2026 | 4 | 7 | 3 | 0 | 0 | 79% | |
| Jan 1, 2026 | 4 | 7 | 3 | 0 | 0 | 79% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 10, 2026
other
Information on the total number of voting rights and shares
<p align="right"><b>REGULATED INFORMATION</b></p>
Jun 10, 2026
other
$110 Million in Aggregate Financings to Accelerate Genio's U.S. Commercial Launch
<p align="center"> <b>$110 Million in Aggregate Financings to Accelerate Genio's U.S. Commercial Launch </b></p>
Jun 10, 2026
offering
Nyxoah Announces Closing of Underwritten Public Offering
<p align="right"><b>REGULATED INFORMATION</b></p>
Jun 5, 2026
offering
Nyxoah Announces Pricing of $95 Million Underwritten Public Offering
<p align="right"><b>INSIDE INFORMATION</b></p>
Jun 4, 2026
other
Nyxoah Announces Proposed Offering of Ordinary Shares
<p align="right"><b>INSIDE INFORMATION</b></p>
Jun 4, 2026
other
Nyxoah Enters New Chapter of Long Term Value Creation
<p align="right"><b>INSIDE INFORMATION</b></p>
May 20, 2026
other
Information on the total number of voting rights and shares
<p align="right"><b>REGULATED INFORMATION</b></p>
May 20, 2026
earnings
Nyxoah Welcomes the Flemish Investors Federation (VFB) at LégiaPark following Q1 2026 Results and U.S. Commercial Momentum
<p align="center"><b>Nyxoah Welcomes the Flemish Investors Federation (VFB) at LégiaPark following Q1 2026 Results and U.S. Commercial Momentum</b></p
May 12, 2026
earnings
Nyxoah Reports First Quarter 2026 Financial and Operating Results
<p align="right"><b>REGULATED INFORMATION</b></p>
May 8, 2026
announcement
Invitation to attend the annual and the extraordinary shareholders’ meetings of the Company to be held on June 10, 2026
<p align="right"><b>REGULATED INFORMATION</b><br>May 8, 2026, 10:05pm CET / 4:05pm ET</p>
Mar 20, 2026
other
Publication relating to transparency notifications
<p align="right"><b>REGULATED INFORMATION</b></p>
Mar 19, 2026
earnings
Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
<p align="right"><b>REGULATED INFORMATION</b></p>
Mar 13, 2026
other
Publication relating to transparency notification
<p align="right"><b>REGULATED INFORMATION</b></p>
Mar 11, 2026
other
Nyxoah to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
<p align="center"><b>Nyxoah</b> <b>to</b> <b>Participate</b> <b>in</b> <b>the Oppenheimer</b> <b>36</b><sup><b>th</b></sup> <b>Annual</b> <b>Healthcar
Mar 5, 2026
earnings
Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
<p align="center"><b>Nyxoah</b> <b>to</b> <b>Release</b> <b>Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026</b></p>